Trials / Conditions / KRAS Activating Mutation
KRAS Activating Mutation
6 registered clinical trials studyying KRAS Activating Mutation.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Ca NCT05669482 | Verastem, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients NCT05375994 | Verastem, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients NCT05074810 | Verastem, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Pat NCT04470674 | Shirish M Gadgeel | Phase 2 |
| Completed | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung NCT04620330 | Verastem, Inc. | Phase 2 |
| Available | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies NCT04566393 | xCures | — |